Regen BioPharma Inc (RGBP)

[29YEARINVESTOR]

Wow! Thanks! I Did a little research! Kaboom
Revenue
$4.8 M
Employees
23
Founded
2016
Amazing!
Checkout RGBP’s latest Dyo Bio Technologies Executive Team & Key Decision Makers
Here’s there updated site!
https://www.datanyze.com/companies/dyo-bio-technologies/473660573
Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) announced a program to accelerate the clinical development of its NR2F6 therapies. The Company intends to combine modified mRNA technology with Regen's existing siRNA ( small interfering RNA) intellectual property targeting the NR2F6 nuclear receptor which has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator.

mRNA is a single-stranded molecule that carries genetic code from DNA in a cell's nucleus to ribosomes (the cell's protein-making machinery).

Regen has filed an Investigational New Drug Application (IND#16928) for their drug termed tCellVax with the U.S. FDA. tCellVax is intended to utilize siRNA to silence NR2F6 activity in human immune cells thereby activating these immune cells in such a way that they can attack cancer cells. The Company believes that adding new intellectual property utilizing modified mRNA will profoundly simplify the drug development process and thus speed development.

Dyo Biotechnologies https://www.datanyze.com/companies/dyo-bio-technologies/473660573 has been contracted to assist Regen with the development of the above mentioned technology.

"I believe our tCellVax drug as it stands today is a potentially major new development in the field of cancer immunotherapy. We believe that by adding our new mRNA intellectual property to tCellVax we can simplify its administration to patients and thus create a much more marketable drug," says David Koos, CEO and Chairman of Regen. "An RNA-based checkpoint inhibitor will be a first-in-class drug."